About 1mg Arsenox Arsenic Trioxide Injection
| Strength |
1mg |
| Form |
Injection |
| Packaging Size |
10ml |
| Brand |
Arsenox |
| Manufactured By |
Intas |
| Treatment |
To Treat Cancer |
| Composition |
Arsenic Trioxide |
Arsenic Trioxide Injection is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Arsenic trioxide is
used to treat a cancer of the blood and bone marrow called acute promyelocytic (pro-MYE-loe-SIT-ik) leukemia, or APL.
Advanced Therapy for Acute Promyelocytic Leukemia (APL)Arsenox Arsenic Trioxide Injection offers a significant advancement in the management of relapsed or refractory APL in both adults and children. As an approved cytotoxic antineoplastic agent, it is used as part of both induction and consolidation treatment phases, thereby improving the prognosis for patients with this challenging form of leukemia. Arsenox should always be administered under experienced medical supervision.
Easy Administration and Safety MonitoringPresented as a clear, colorless solution, Arsenox is ready for immediate use without the need for reconstitution. It is exclusively for intravenous infusion in a controlled clinical setting. Continuous monitoring of cardiac health and organ function ensures patient safety throughout the course of treatment, particularly regarding potential effects such as QT prolongation and hepatic dysfunction.
FAQ's of 1mg Arsenox Arsenic Trioxide Injection:
Q: How is Arsenox Arsenic Trioxide Injection administered to patients?
A: Arsenox is administered intravenously via infusion under strict medical supervision. Only trained healthcare professionals should prepare and deliver the dose, following the specific instructions provided by the prescribing physician.
Q: What are the primary benefits of using Arsenox for Acute Promyelocytic Leukemia (APL)?
A: The main benefit of Arsenox lies in its proven effectiveness for both induction and consolidation treatment phases in relapsed or refractory APL, helping to improve response rates and overall survival outcomes in adults and pediatric patients.
Q: When should Arsenox Injection be used during leukemia treatment?
A: Arsenox is indicated for the treatment of relapsed or refractory cases of Acute Promyelocytic Leukemia (APL). It should be used according to the treatment plan and timeline established by the oncologist or hematologist managing the patient's care.
Q: Where should Arsenox be stored before use?
A: Arsenox should be stored below 25C and protected from light. The vial must be kept in its original packaging up until use and should be used immediately after opening to maintain sterility and efficacy.
Q: What monitoring is required while receiving Arsenox therapy?
A: Patients receiving Arsenox should have regular ECGs and laboratory checks for electrolytes and liver function. This is essential because the drug may cause QT prolongation, hepatic dysfunction, and changes in white blood cell counts.
Q: Who should not receive Arsenox Arsenic Trioxide Injection?
A: Arsenox is contraindicated in individuals with known hypersensitivity to arsenic trioxide. Special caution is advised for patients with pre-existing cardiac disorders or liver impairment; such cases require close monitoring.